IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP

Not yet recruiting

• Conditions: ITP
• Interventions: Drug: Corticosteriod for treated patients

• Registration Number: NCT04482777
• Lead Sponsor: Assiut University

Brief Summary

To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

Detailed Description

Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.

Study Timeline

• Study First Submitted: 2020-07-19
• Study First Submitted QC: 2020-07-19
• Study First Posted: 2020-07-23
• Study Start: 2023-07-30
• Status Verified: 2023-08
• Primary Completion: 2023-08-01
• Last Update Submitted: 2023-08-07
• Last Update Posted: 2023-08-09
• Study Completion: 2023-09-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with ITP (moderate and sever) different age group.

Exclusion Criteria

• Patients with stroke and myocardial infarction,malignant tumors or pregnancy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
ITP	Corticosteriod for treated patients	Patient newly diagnosied with ITP
Treated	Corticosteriod for treated patients	Patients with ITP recived treatment
Control	Corticosteriod for treated patients	Healthy people

Primary Outcome Measures

Name	Time	Method
To decrease the immunity complications in ITP patients	Baseline	Early detection of immunity complications in ITP patients
To decrease case fatality rate	Baseline	Early detection of immunity complication will decrease mortality rate